舒心素胶囊治疗冠心病心绞痛临床观察

Clinical Observation of the Effect of Shuxinsu Capsule in Treating Angina Pectoris

目的:观察舒心素胶囊治疗冠心病心绞痛的临床疗效。方法:共观察冠心病心绞痛患者150例,其中80例采用双盲法分为两组,即舒心素胶囊治疗组和益心口服液对照组各40例,其余70例为开放治疗组。结果:双盲治疗组缓解冠心病心绞痛有效16例,显效17例,总有效率为8250%;双盲对照组有效16例、显效13例,总有效率为7250%,双盲治疗组疗效优于对照组(u=199,P<005)。对心电图的疗效,总治疗组110例,有效30例,显效34例,总有效率为5818%,对照组的总有效率为5500%,组间比较无显著性差异(P>005);治疗后增加红细胞SOD活力和降低血浆LPO含量,与治疗前比较有显著差异(t=672、t=730,均P<001);对血脂TC、TG两药都有一定的降低作用。治疗组降低血清TC及提高HDL-C水平,与治疗前比较均有显著性差异(t=306、t=369,P<001)。结论:舒心素胶囊对冠心病心绞痛有较好的治疗作用。

To observe the therapeutic effect of Shuxinsu capsule (SXSC) in treating angina pectoris patients. Methods: One hundred and fifty angina pectoris patients were divided into two groups. Group A (80 cases), randomly divided into two subgroups, SXSC treated and Yixin oral liquid (YXOL) control group, each group consisted of 40 cases. Group B (70 cases) was an openly treated group (OTG). Results: 17 cases were markedly effective in the SXSC treated group in relieving the symptoms, effective were 16, the total effective rate was 82.50%, while in the control group, the markedly effective cases, the effective cases and the total effective rate were 13, 16 and 72.50% respectively; there was significant difference between these two groups (u=1.99, P<0 05). In the treated group (SXSC and OTG) of 110 cases, the markedly effective, effective cases on ECG were 34 and 30 respectively. The total effective rate was 58.18%, higher than that of the control group, which was 55.00%, but the difference was insignificant. The activity of SOD in RBC and the amount of plasma LPO were significantly different after treatment in the SXSC group. Both of the medications had effect to reduce serum total cholesterol (TC) and triglyceride (TG), the TC was lower and high density lipoprotein cholesterol (HDL C) higher significantly after treatment in the SXSC group. Conclusion: SXSC has significant effect on angina pectoris.